Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design

References

• Gordon MH. Dietary antioxidants in disease prevention. Nat Prod Rep 1996;13:265–73.
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Schluesener H. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res Rev 2012;11:329–45.
   PubMed Web of Science ®Google Scholar
• Kamal M, Naz M, Jawaid T, Arif M. Natural products and their active principles used in the treatment of neurodegenerative diseases: a review. Orient Pharm Exp Med 2019;19:343–23.
   Web of Science ®Google Scholar
• Pandey KB, Rizvi SI. Current understanding of dietary polyphenols and their role in health and current understanding of dietary polyphenols and their role in health and disease. Curr Nutr Food Sci 2009;5: 249–263.
   Google Scholar
• Hung H, Joshipura KJ, Jiang R, et al. Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 2004;96:1577–84.
   PubMed Web of Science ®Google Scholar
• Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010;15:7792–814.
   PubMed Web of Science ®Google Scholar
• Gollucke A, Peres RO Jr, Ribeiro D. A nutraceutical approach against diseases. Recent Pat Food Nutr Agric 2014;5:214–9.
   Google Scholar
• Spencer JPE, Abd MM, Mohsen E, Minihane A, et al. Review article biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research. 2008;99:12–22.
   Google Scholar
• Choi DY, Lee YJ, Hong JT, Lee HJ. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull 2012;87:144–53.
   PubMed Web of Science ®Google Scholar
• Panda SS, Jhanji N. Natural products as potential anti-Alzheimer agents. Curr Med Chem 2019. doi:10.2174/0929867326666190618113613
   PubMed Web of Science ®Google Scholar
• Solayman M, Islam M, Alam F, et al. Natural products combating neurodegeneration: parkinson’s disease. Curr Drug Metab 2017;18:50–61.
   PubMed Web of Science ®Google Scholar
• Khatoon SS, Rehman M, Rahman A, The role of natural products in Alzheimer’s and Parkinson’s disease. Studies in natural products chemistry. Vol. 56. Amsterdam (Netherlands): Elsevier; 2018:69–127.
   Google Scholar
• Bawari S, Tewari D, Argüelles S, et al. Targeting BDNF signaling by natural products: novel synaptic repair therapeutics for neurodegeneration and behavior disorders. Pharmacol Res 2019;148:104458.
   PubMed Web of Science ®Google Scholar
• Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Design 2006;67:27–37.
   PubMed Web of Science ®Google Scholar
• Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci 2013;14:12411–57.
   PubMed Web of Science ®Google Scholar
• Gazit E. Mechanisms of amyloid fibril self-assembly and inhibition Model short peptides as a key research tool. FEBS J 2005;272:5971–8.
   PubMed Web of Science ®Google Scholar
• Nencetti S, Orlandini E. TTR fibril formation inhibitors: is there a SAR? Curr Med Chem 2012;19:2356–79.
   PubMed Web of Science ®Google Scholar
• Martone R, Herbert J, Dwork AA, Schon E. Transthyretin is synthesized in the mammalian eye. Biochem Biophys Res Commun 1988;151:905–12.
   PubMed Web of Science ®Google Scholar
• Landers KA, Mortimer RH, Richard K. Transthyretin and the human placenta. Placenta 2013;34:513–7.
   PubMed Web of Science ®Google Scholar
• Hamilton J. a, Benson MD. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001;58:1491–521.
   PubMed Web of Science ®Google Scholar
• Naylor HM, Newcomer ME. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 1999;38:2647–53.
   PubMed Web of Science ®Google Scholar
• Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS One 2008;3:e2899.
   PubMed Web of Science ®Google Scholar
• Alemi M, Silva SC, Santana I, Cardoso I. Transthyretin stability is critical in assisting beta amyloid clearance – Relevance of transthyretin stabilization in Alzheimer ‘s disease. CNS Neurosci Ther 2017;23:605–19.
   PubMed Web of Science ®Google Scholar
• Cotrina EY, Gimeno A, Llop J. Calorimetric studies of binary and ternary molecular interactions between transthyretin, Aβ peptides and small-molecule chaperones towards an alternative strategy for Alzheimer’s Disease drug discovery. J Med Chem 2020;63:3205–14.
   PubMed Web of Science ®Google Scholar
• Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998;158:47–52.
   PubMed Web of Science ®Google Scholar
• Leal SS, Botelho HM, Gomes CM. Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coord Chem Rev 2012;256:2253–70.
   Web of Science ®Google Scholar
• Ciccone L, Policar C, Stura EA, Shepard W. Human TTR conformation altered by rhenium tris-carbonyl derivatives. J Struct Biol 2016;195:353–64.
   PubMed Web of Science ®Google Scholar
• Ciccone L, Fruchart-gaillard C, Mourier G, et al. Copper mediated amyloid- β binding to. Transthyretin Sci Rep 2018;8:1–11.
   PubMed Web of Science ®Google Scholar
• Blake CCF, Swan IDA, Rerat C, et al. An X-ray study of the subunit structure of prealbumin. J Mol Biol 1971;61:217–24.
   PubMed Web of Science ®Google Scholar
• Wojtczak A, Cody V, Luft JR, Pangborn W. Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 Åresolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites. Acta Crystallogr Sect D Biol Crystallogr 2001;57:1061–70.
   PubMedGoogle Scholar
• Ferguson RN, Edelhoch H, Saroff HA, et al. Negative cooperativity in the binding of thyroxine to human serum prealbumin. Biochemistry 1975;14:282–9.
   PubMed Web of Science ®Google Scholar
• Neumann P, Cody V, Wojtczak A. Structural basis of negative cooperativity in transthyretin. Acta Biochim Pol 2001;48:867–75.
   PubMed Web of Science ®Google Scholar
• Correlation AC. Frequency and distribution of senile cardiovascular amyloid a clinicopathologic correlation. Am J Med 1983;75:618–23.
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants. Amyloid 2003;10:160–84.
   PubMed Web of Science ®Google Scholar
• Jobo M, Saraiva M, Costa PP, Goodman DS. Biochemical marker in familial amyloidotic polyneuropathy. Portuguese Type 1985;76:2171–7.
   Google Scholar
• Angeles L. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black americans. N Engl J Med 1997;336:466–73.
   PubMed Web of Science ®Google Scholar
• Munar-ques M, Costa PP, Saraiva MJM, et al. Familial amyloidotic polyneuropathy. TTR Met 30 in Majorca (Spain). J Protein Fold Disord 2009;4:181–6.
   Web of Science ®Google Scholar
• Araki S. Type I familial amyloidotic polyneuropathy oapanese type. Brain Dev 1984;6:128–33.
   PubMed Web of Science ®Google Scholar
• Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004;47:355–74.
   PubMed Web of Science ®Google Scholar
• Compounds S. Inhibition of the amyloidogenesis of transthyretin by natural products and synthetic compounds. Biol Pharm Bull 2018;41:979–84.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260:2802–14.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658–67.
   PubMed Web of Science ®Google Scholar
• Nencetti S, Rossello A, Orlandini E. Tafamidis (vyndaqel): a light for FAP patients. ChemMedChem 2013;8:1619.
   Web of Science ®Google Scholar
• Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov 2012;11:185–6.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Maurer MS. Tafamidis—a pricey therapy for a not-so-rare condition. JAMA Cardiol 2020;5:247.
   PubMed Web of Science ®Google Scholar
• Palaninathan SK. Nearly 200 x-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem 2012;19:2324–42.
   PubMed Web of Science ®Google Scholar
• Trivella DBB, dos Reis CV, Lima Maurício LTR, et al. Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. J Struct Biol 2012;180:143–53.
   PubMed Web of Science ®Google Scholar
• Iakovleva I, Begum A, Pokrzywa M, et al. The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response. PLoS One 2015;10:e0128222.
   PubMed Web of Science ®Google Scholar
• Nilsson L, Larsson A, Begum A, et al. Modifications of the 7-hydroxyl group of the transthyretin ligand luteolin provide mechanistic insights into its binding properties and high plasma specificity. PLoS One 2016;11:e0153112.
   PubMed Web of Science ®Google Scholar
• Cianci M, Folli C, Zonta F, et al. Structural evidence for asymmetric ligand binding to transthyretin. Acta Crystallogr D Biol Crystallogr 2015;71:1582–92.
   PubMed Web of Science ®Google Scholar
• Trivella DBB, Bleicher L, Palmieri LDC, et al. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J Struct Biol 2010;170:522–31.
   PubMed Web of Science ®Google Scholar
• Florio P, Folli C, Cianci M, et al. Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites. J Biol Chem 2015;290:29769–80.
   PubMed Web of Science ®Google Scholar
• Miyata M, Sato T, Kugimiya M, et al. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 2010;49:6104–14.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Ueda M, Ando Y, Mizuguchi M. Discovery of γ-mangostin as an amyloidogenesis inhibitor. Sci Rep 2015;5:13570.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kosaka Y, Mizuguchi M. Crystal structures of human transthyretin complexed with glabridin. J Med Chem 2014;57:1090–6.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kosaka Y, Mizuguchi M. Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin. J Med Chem 2014;57:8928–35.
   PubMed Web of Science ®Google Scholar
• Zanotti G, D'acunto MR, Malpeli G, et al. Crystal structure of the transthyretin-retinoic-acid complex. Eur J Biochem 1995;234:563–9.
   PubMedGoogle Scholar
• Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000;7:312–21.
   PubMedGoogle Scholar
• Ciccone L, Tepshi L, Nencetti S, Stura EA. Transthyretin complexes with curcumin and bromo-estradiol: evaluation of solubilizing multicomponent mixtures. N Biotechnol 2015;32:54–64.
   PubMed Web of Science ®Google Scholar
• Polsinelli I, Nencetti S, Shepard W, et al. A new crystal form of human transthyretin obtained with a curcumin derived ligand. J Struct Biol 2016;194:8–17.
   PubMed Web of Science ®Google Scholar
• Bors W, Heller W, Michel C, et al. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Oxygen radicals in biological systems part B: oxygen radicals and antioxidants. Vol. 186. Cambridge (MA): Academic Press; 1990:343–55. doi:
   Google Scholar
• Spagnuolo C, Moccia S, Russo GL. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur J Med Chem 2018;153:105–15.
   PubMed Web of Science ®Google Scholar
• Maher P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int J Mol Sci 2019;20:3056.
   Web of Science ®Google Scholar
• Nabavi SF, Braidy N, Gortzi O, et al. Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull 2015;119:1–11.
   PubMed Web of Science ®Google Scholar
• Schreihofer DA, Redmond L. Soy phytoestrogens are neuroprotective against stroke-like injury in vitro. Neuroscience 2009;158:602–9.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Fu J, Li S, Li Z. Neuroprotective effects of genistein in a SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2019;14:688–96.
   PubMed Web of Science ®Google Scholar
• Zepeda RC. Genistein as potential therapeutic candidate for menopausal symptoms and other related diseases. Molecules. 2019;24:3892.
   Web of Science ®Google Scholar
• Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA 2005;102:14545–50.
   PubMed Web of Science ®Google Scholar
• Radović B, Mentrup B, Köhrle J. Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. Br J Nutr 2006;95:1171–6.
   PubMed Web of Science ®Google Scholar
• Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001;21:2–14.
   PubMed Web of Science ®Google Scholar
• Kim JW, Jin YC, Kim YM, et al. Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-kB activation. Life Sci 2009;84:227–34.
   PubMed Web of Science ®Google Scholar
• Hertog MGL, Hollman PCH, van de Putte B. Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juices. J Agric Food Chem 1993;41:1242–6.
   Web of Science ®Google Scholar
• Aras AB, Guven M, Akman T, et al. Neuroprotective effects of daidzein on focal cerebral ischemia injury in rats. Neural Regen Res 2015;10:146–52.
   PubMed Web of Science ®Google Scholar
• Wei J, Yang F, Gong C, et al. Protective effect of daidzein against streptozotocin-induced Alzheimer’s disease via improving cognitive dysfunction and oxidative stress in rat model. J Biochem Mol Toxicol 2019;e22319.
   PubMed Web of Science ®Google Scholar
• Venigalla M, Gyengesi E, Münch G. Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural Regen Res 2015;10:1181–5.
   PubMed Web of Science ®Google Scholar
• Salehi B, Venditti A, Sharifi-Rad M, et al. The therapeutic potential of Apigenin. Int J Mol Sci 2019;20:1305.
   PubMed Web of Science ®Google Scholar
• Cho S, Park S, Kwon M, et al. Quercetin suppresses proinflammatory cytokines production through MAP kinases and NF- κ B pathway in lipopolysaccharide-stimulated macrophage. Mol Cell Biochem 2003;243:153–60.
   PubMed Web of Science ®Google Scholar
• Boly R, Gras T, Lamkami T, et al. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol 2011;38:833–42.
   PubMed Web of Science ®Google Scholar
• Dajas F. Life or death: neuroprotective and anticancer effects of quercetin. J Ethnopharmacol 2012;143:383–96.
   PubMed Web of Science ®Google Scholar
• Elumalai P, Lakshmi S, Role of quercetin benefits in neurodegeneration. The benefits of natural products for neurodegenerative diseases. Berlin, Germany: Springer; 2016:229–45.
   Google Scholar
• Paula PC, Maria SGA, Luis CH, Patricia C. Preventive effect of quercetin in a triple transgenic Alzheimer’s disease mice model. Molecules 2019;24:2287–10.
   Web of Science ®Google Scholar
• M. Calderon-Montano J, Burgos-Moron E, Perez-Guerrero C, Lopez-Lazaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011;11:298–344.
   PubMed Web of Science ®Google Scholar
• Imran M, Salehi B, Sharifi-Rad J, et al. Kaempferol: a key emphasis to its anticancer potential. Molecules 2019;24:2277–16.
   PubMed Web of Science ®Google Scholar
• Salehi B, Fokou PVT, Sharifi-Rad M, et al. The therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals 2019;12:11–8.
   Web of Science ®Google Scholar
• Magalingam KB, Radhakrishnan AK, Haleagrahara N. Protective mechanisms of flavonoids in Parkinson’s disease. Oxid Med Cell Longev 2015;2015:1–14.
   Web of Science ®Google Scholar
• Chen C, Wei YZ, He XM, et al. Naringenin produces neuroprotection against LPS-induced dopamine neurotoxicity via the inhibition of microglial NLRP3 inflammasome activation. Front Immunol 2019;10:1–13.
   PubMed Web of Science ®Google Scholar
• Cipolletti M, Montalesi E, Nuzzo MT, et al. Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β-estradiol/estrogen receptor α/neuroglobin pathway. J Cell Physiol 2019;234:3147–57.
   PubMed Web of Science ®Google Scholar
• Gan RY, Li H, Bin Sui ZQ, et al. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review. Crit Rev Food Sci Nutr 2018;58:924–41.
   PubMed Web of Science ®Google Scholar
• Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J 2015;15:1–17.
   Web of Science ®Google Scholar
• Farkhondeh T, Yazdi HS, Samarghandian S. The protective effects of green tea catechins in the management of neurodegenerative diseases: a review. Curr Drug Discov Technol 2019;16:57–65.
   PubMedGoogle Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011;585:2424–30.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Jo M, Ros M. Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis. Int J Mol Sci 2019;20:1287.
   Web of Science ®Google Scholar
• Ortore G, Orlandini E, Braca A, et al. Targeting different transthyretin binding sites with unusual natural compounds. ChemMedChem 2016;11:1865–74.
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci 2012;109:9629–34.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–16.
   PubMed Web of Science ®Google Scholar
• Yukio A, Yoshiki S, Konen O, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: a phase III, open-label study. J Neurol Sci 2016;362:266–71.
   PubMed Web of Science ®Google Scholar
• Keohane D, Schwartz J, Gundapaneni B, et al. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Randomized Controlled Trial 2017;24:30–6.
   Google Scholar
• Falk RH. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur Heart J 2019;40:1009–12.
   PubMed Web of Science ®Google Scholar
• Chang H, Yang L. Gamma-mangostin, a micronutrient of mangosteen fruit, induces apoptosis in human colon cancer cells. Molecules 2012;17: 8010–21.
   PubMed Web of Science ®Google Scholar
• Ashton MM, Dean OM, Walker AJ, et al. The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia. Front Psychiatry 2019;10:1–17.
   PubMed Web of Science ®Google Scholar
• Simmler C, Pauli GF, Chen S. Fitoterapia phytochemistry and biological properties of glabridin. Fitoterapia 2013;90:160–84.
   PubMed Web of Science ®Google Scholar
• Morais-de-Sá E, Pereira PJB, Saraiva MJ, Damas AM. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J Biol Chem 2004;279:53483–90.
   PubMed Web of Science ®Google Scholar
• Sawicka D, Car H, Borawska MH, Nikliński J. The anticancer activity of propolis. Folia Histochem Cytobiol 2012;50:25–37.
   PubMed Web of Science ®Google Scholar
• Jeong CH, Jeong HR, Choi GN, Kim DO, et al. Neuroprotective and anti-oxidant effects of caffeic acid isolated from Erigeron annuus leaf. Chin Med 2011;6:25.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu Z, Meng J, et al. The neuroprotective effects of Brazilian green propolis on neurodegenerative damage in human neuronal SH-SY5Y cells. Oxid Med Cell Longev 2017;2017:1–13.
   Web of Science ®Google Scholar
• Morroni F, Sita G, Graziosi A, et al. Neuroprotective effect of caffeic acid phenethyl ester in a mouse model of alzheimer’s disease involves Nrf2/HO-1 pathway. Aging Dis 2018;9:605–22.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Davis FB, Deziel MR, et al. Retinoic acid inhibition of thyroxine binding to human transthyretin. BBA Gen Subj 1994;1199:76–80.
   PubMed Web of Science ®Google Scholar
• Kollár P, Hotolová H. Biological effects of resveratrol and other constituents of wine. Ces Slov Farm 2003;52:272–81.
   PubMedGoogle Scholar
• Udenigwe CC, Ramprasath VR, Aluko RE, Jones P. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 2008;66:445–54.
   PubMed Web of Science ®Google Scholar
• Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010;41:375–83.
   PubMed Web of Science ®Google Scholar
• Tellone E, Galtieri A, Russo A, et al. Resveratrol: a focus on several neurodegenerative diseases. Oxid Med Cell Longev 2015;2015:1–14.
   Web of Science ®Google Scholar
• Wąsik A, Antkiewicz-Michaluk L. The mechanism of neuroprotective action of natural compounds. Pharmacol Rep 2017;69:851–60.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40–59.
   PubMed Web of Science ®Google Scholar
• Maiti P, Dunbar GL. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci 2018;19:1637.
   PubMed Web of Science ®Google Scholar
• Thapa A, Jett SD, Chi EY. Curcumin attenuates amyloid-β aggregate toxicity and modulates amyloid-β aggregation pathway. ACS Chem Neurosci 2016;7:56–68.
   PubMed Web of Science ®Google Scholar
• Pullakhandam R, Srinivas P, Nair MK, Reddy GB. Binding and stabilization of transthyretin by curcumin. Arch Biochem Biophys 2009;485:115–9.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Gonçalves NP, Saraiva MJ, Almeida MR. Curcumin: a multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Sci Rep 2016;6:26623.
   PubMed Web of Science ®Google Scholar
• Polsinelli I, Savko M, Rouanet-Mehouas C, et al. Comparison of helical scan and standard rotation methods in single-crystal X-ray data collection strategies. J Synchrotron Radiat 2017;24:42–52.
   PubMed Web of Science ®Google Scholar